Tiziana Life Sciences CEO believes breast cancer technology could become an "essential prognostic tool”

Tiziana Life Sciences PLC’s (LON:TILS, NASDAQ:TLSA) chief executive believes the company’s StemPrintER technology has the “potential to become an essential prognostic tool” in the fight against breast cancer. Kunwar Shailubhai’s comment followed the release of a scientific abstract ahead of a poster discussion session at the American Society of Clinical Oncology’s (ASCO) virtual conference being held later this month. This poster showed the stem cell biology-based genomic tool had “greater refinement [than] and superiority [to]” than the current market leader, Oncotype DX, in delivering prognostic information on women with ER+/HER2- form of breast cancer. The results were compiled by the European Institute of Oncology in Milan in collaboration with the Royal Marsden Hospital and Queen Mary University in London. In a statement, Tiziana CEO Shailubhai said: "These data sets demonstrate that StemPrintER has the potential to become an essential prognostic tool that will help clinicians to tailor more or less aggressive therapy based on a more accurate risk assessment of disease recurrence compared to what we have seen to date. "This product also represents an important addition to our existing therapeutic pipeline as it opens Tiziana into the area of precision medicine, creating an entirely new business line beyond our current patented technology in offering new delivery mechanisms for monoclonal antibodies." An additional abstract from the scientists at the European Institute of Oncology will be presented in a separate poster session. This will assess the potential of StemPrintER in “distant metastasis prediction”. Both abstracts became available May 13, while the posters and discussion session will be held during the conference from May 29-31.